Tscan Therapeutics Inc (TCRX) — Strategic Asset Allocation Index
Tscan Therapeutics Inc (TCRX) has a Strategic Asset Allocation Index of 35.7% as of June 2023. Strategic assets (PP&E of $68.03 Million plus long-term investments of $-) total $68.03 Million, measured against net assets of $190.61 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check Tscan Therapeutics Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Tscan Therapeutics Inc Strategic Asset Allocation Index (2019–2022)
This chart shows how Tscan Therapeutics Inc's Strategic Asset Allocation Index has evolved across 3 annual periods from 2019 to 2022. As of June 2023, the index stands at 35.7%, representing strategic assets of $68.03 Million against net assets of $190.61 Million USD. See financial agility of Tscan Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Tscan Therapeutics Inc (2019–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Tscan Therapeutics Inc from 2019 to 2022, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see how much is Tscan Therapeutics Inc worth.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 10.2% | $10.10 Million | $10.10 Million | $- | $99.43 Million | ▲ +2.8 pp |
| 2021 | 7.3% | $11.77 Million | $11.77 Million | $- | $160.78 Million | ▼ -7.7 pp |
| 2019 | 15.1% | $6.41 Million | $6.41 Million | $- | $42.54 Million | — |